Cargando…

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease, and may be the main reason for the failure of AD drug development. Fortunately, many ongoing preclin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Chenghuan, Shi, Jiyun, Zhang, Pingao, Zhang, Yongfang, Xu, Jianrong, Zhao, Lanxue, Zhang, Rui, Wang, Hao, Chen, Hongzhuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932191/ https://www.ncbi.nlm.nih.gov/pubmed/35300725 http://dx.doi.org/10.1186/s40035-022-00292-3

Ejemplares similares

Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of β-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer’s Disease
por: Wang, Yu, et al.
Publicado: (2019)

Multifunctional Anti-Alzheimer’s Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation
por: Hu, Xiaoyu, et al.
Publicado: (2022)

Structural Insights into M1 Muscarinic Acetylcholine Receptor Signaling Bias between Gαq and β-Arrestin through BRET Assays and Molecular Docking
por: Wang, Dongxue, et al.
Publicado: (2023)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

Cu(II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation
por: Yu, Fengxiang, et al.
Publicado: (2015)

Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond β-Amyloid: Insights from Clinical Trials
por: Jia, Qiutian, et al.
Publicado: (2014)

Sleep in Alzheimer's Disease–Beyond Amyloid
por: Holth, Jerrah K., et al.
Publicado: (2016)

Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease
por: Dawkins, Edgar, et al.
Publicado: (2014)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
por: Crespi, Gabriela A. N., et al.
Publicado: (2015)

Bis(9)-(−)-Meptazinol, a novel dual-binding AChE inhibitor, rescues cognitive deficits and pathological changes in APP/PS1 transgenic mice
por: Shi, Yuhuan, et al.
Publicado: (2018)

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
por: Moreth, Jens, et al.
Publicado: (2013)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Targeting the γ-/β-secretase interaction reduces β-amyloid generation and ameliorates Alzheimer’s disease-related pathogenesis
por: Cui, Jin, et al.
Publicado: (2015)

Alzheimer's Progenitor Amyloid‐β Targets and Dissolves Microbial Amyloids and Impairs Biofilm Function
por: Ali, Syed Aoun, et al.
Publicado: (2023)

Amyloid PET imaging: applications beyond Alzheimer’s disease
por: Catafau, Ana M., et al.
Publicado: (2015)

Beyond amyloid: New approaches to Alzheimer's disease treatment
Publicado: (2020)

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
por: Weller, Roy O, et al.
Publicado: (2009)

MRAβ: A multimodal MRI‐derived amyloid‐β biomarker for Alzheimer's disease
por: Zhang, Yu, et al.
Publicado: (2023)

Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
por: Zhang, Yun, et al.
Publicado: (2023)

The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
por: Zhang, Xingyu, et al.
Publicado: (2018)

Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease
por: Pan, Xiao-dong, et al.
Publicado: (2011)

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2015)

Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Mitochondria, Amyloid β, and Alzheimer's Disease
por: Readnower, Ryan D., et al.
Publicado: (2011)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

An “Amyloid‐β Cleaner” for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction
por: Liu, Ruiyuan, et al.
Publicado: (2019)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020)

(Dys)regulation of Synaptic Activity and Neurotransmitter Release by β-Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis
por: Fagiani, Francesca, et al.
Publicado: (2021)

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis
por: Mo, Jia‐Jie, et al.
Publicado: (2017)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vht5vc8c0cf5r8p27qu1oh68in